Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-8931

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

Biogen Idec building

Biogen buys into Rodin’s Alzheimer’s candidate

And may acquire the epigenetics-focused Massachusetts firm

- PMLiVE

Axovant takes Alzheimer’s drug into phase III

Aims to bring first treatment in a decade to market

UK Life Sciences Strategy - one year on

Genome diagnostic can see if a patient is ‘ageing well’

Test can predict risk of age-related diseases and age of death

- PMLiVE

Amgen and Novartis collaborate on Alzheimer’s research

Will work on the development and commercialisation of BACE inhibitors

Biogen Idec building

Biogen Idec plans phase III Alzheimer’s trial before year-end

And MS drugs drive 2014 sales          

EU flag

Pharma joins European Alzheimer’s research initiative

Lilly and Janssen among participants of dementia-focused IMI project

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

- PMLiVE

Medical device M&A hit ‘all-time high’ in 2014

Deals last year were led by Medtronic’s acquisition of Covidien

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

- PMLiVE

Alzheimer’s charity launches £20m trials fund

Aims to fast-track research into dementia treatments

- PMLiVE

UPDATE: Merck to acquire Cubist for $8.4bn

Will expand company's presence in antibiotics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links